IFN-γ Enhances the Therapeutic Effect of Mscs on Experimental Renal Fibrosis

CURRENT STATUS: Posted

Ryo Kanai, Ayumu Nakashima, Shigehiro Doi, Tomoe Kimura, Ken Yoshida, Satoshi Maeda, Naoki Ishiuchi, Yumi Yamada, Takeshi Ike, Toshiki Doi, Yukio Kato, Takao Masaki

Ryo Kanai
Hiroshima Daigaku Byoin

Ayumu Nakashima
Hiroshima University, Graduate School of Biomedical & Sciences
ayumu@hiroshima-u.ac.jp Corresponding Author
ORCID: https://orcid.org/0000-0002-7838-1494

Shigehiro Doi
Hiroshima Daigaku Byoin

Tomoe Kimura
Hiroshima Daigaku Byoin

Ken Yoshida
Hiroshima Daigaku Byoin

Satoshi Maeda
Hiroshima Daigaku Byoin

Naoki Ishiuchi
Hiroshima Daigaku Byoin

Yumi Yamada
Hiroshima Daigaku Byoin

Takeshi Ike
Hiroshima Daigaku Byoin

Toshiki Doi
Hiroshima Daigaku Byoin

Yukio Kato
Hiroshima Daigaku Byoin

Takao Masaki
Hiroshima Daigaku Byoin
Subject Areas

*Stem Cell & Developmental Cell Biology*

Keywords

*Mesenchymal stem cells, Interferon-γ, Prostaglandin E2, Anti-inflammation, Renal fibrosis*
Abstract

Background:
Mesenchymal stem cells (MSCs) administered for therapeutic purposes can be activated by interferon-γ (IFN-γ) secreted from natural killer cells in injured tissues and exert anti-inflammatory effects. These processes may require a substantial period of time, leading to a delayed onset of MSCs therapeutic effects. Here, we investigated whether pretreatment with IFN-γ potentiates the anti-fibrotic and anti-inflammatory activities of MSCs in an injured kidney.

Methods:
MSCs with or without IFN-γ treatment were injected into rats after ischemia-reperfusion injury (IRI) or unilateral ureter obstruction (UUO) to evaluate the therapeutic effect of IFN-γ-treated MSCs. In addition, we used conditioned medium obtained from IFN-γ-treated MSCs to investigate fibrotic change in cultured cells induced by transforming growth factor-β1 and phenotypic change of macrophages using THP-1 monocytes.

Results:
Administration of MSCs treated with IFN-γ strongly ameliorated renal fibrosis and inflammation in rat IRI and UUO models compared with that of untreated MSCs. In vitro experiments demonstrated that IFN-γ treatment enhanced the anti-fibrotic effects of MSCs by inhibiting the transforming growth factor-β1/Smad signaling pathway. Most notably, secretion of prostaglandin E2 from MSCs was significantly increased by treatment with IFN-γ. Increased prostaglandin E2 induced polarization of immunosuppressive CD163-positive macrophages. In addition, knockdown of prostaglandin E synthase weakened the anti-fibrotic effects of MSCs treated with IFN-γ in IRI rats, suggesting the involvement of prostaglandin E2 in the beneficial effects of IFN-γ.

Conclusions:
Administration of MSCs treated with IFN-γ may represent a promising therapy to prevent the progression of renal fibrosis.

Background

The morbidity rate of chronic kidney disease (CKD) is estimated to be 8–16% worldwide [1]. Etiological studies of CKD have reported multiple causes of disease initiation including hypertension, diabetes mellitus, and glomerulonephritis [2]. Despite differences in disease initiation, renal fibrosis exacerbated by persistent inflammation is a histological change common to all these etiologies [3, 4]. Currently there are few effective treatments that prevent the progression of CKD and many patients eventually develop renal failure, which requires renal replacement therapy [5], resulting in a heavy social and economic burden. Therefore, there is an urgent need for the development of novel therapeutic strategies to treat renal fibrosis associated with CKD.

The pathogenesis of CKD is mediated by inflammatory cells, which cause renal fibrosis via fibroblast activation and increased extracellular matrix deposition [5, 6]. Damage-associated molecular patterns (DAMPs) released from damaged tissues activate the local immune system and several studies reported DAMPs were involved in promoting renal fibrosis [7–9]. In CKD patients, the inflammatory microenvironment is maintained by infection, uremic toxins, or tissue ischemia [10], and this chronic inflammation contributes to the sustained release of DAMPs from injured kidney tissues, which induces further inflammation and fibrosis. Therefore, the inhibition of inflammation is expected to ameliorate renal fibrosis.

Mesenchymal stem cells (MSCs) isolated from various tissues including bone marrow, blood, and adipose tissue [11, 12], have multipotency and self-renewal ability [13, 14]. They exert their beneficial effects by suppressing inflammation and fibrosis via a paracrine mechanism [15, 16]. High mobility group box-1 protein (HMGB1) and
interleukin-18 (IL-18) are members of DAMPs—HMGB1 was reported to promote the migration of MSCs [17, 18], whereas IL-18 contributed to the secretion of interferon-γ (IFN-γ) from natural killer cells [19]. Furthermore, IFN-γ released from immune cells at sites of damaged tissues stimulated MSCs to secrete anti-inflammatory mediators including prostaglandin E2 (PGE2) [20–22], which inhibited the production of inflammatory cytokines [23–25]. PGE2 also induced the polarization of immunosuppressive M2 macrophages that produce anti-inflammatory cytokines and inhibit the persistence of inflammation [26, 27]. In addition, we previously reported that MSCs promoted macrophage differentiation from an M1 pro-inflammatory phenotype to an immunosuppressive M2 phenotype, and that the administration of ex vivo-expanded MSCs suppressed the progression of fibrosis [28, 29]. Taken together, this suggests that IFN-γ-preconditioned MSCs have a strong immunosuppressive effect and therefore might ameliorate renal fibrosis. However, the utility of MSCs cultured with IFN-γ for the treatment of kidney disease has not been investigated.

This study investigated the therapeutic effect of MSCs cultured in IFN-γ-containing medium on inflammation and fibrosis using rat ischemia-reperfusion injury (IRI) and unilateral ureter obstruction (UUO) models.

**Methods**

**Animals**

Male Sprague-Dawley (SD) rats were purchased from Charles River Laboratories Japan (Yokohama, Japan). Six-week-old rats were used to collect bone marrow, and 8-week-old rats were used in in vivo experiments. All experiments were performed according to the “Guide for the Care and Use of Laboratory Animals, 8th ed., 2010” (National Institutes of Health, Bethesda, MD) and approved by the Institutional Animal Care and Use Committee of Hiroshima University (Permit number: A15-66 and A17-75).

**Antibodies**

As primary antibodies, we used a rabbit monoclonal anti-HMGB1 antibody (ab79823; Abcam, Cambridge, UK), rabbit monoclonal anti-IL-18 antibody (ab223293; Abcam), rabbit monoclonal anti-IFN-γ antibody (ab133566; Abcam), mouse monoclonal anti-α-smooth muscle actin (α-SMA) antibody (A-2547; Sigma-Aldrich; St. Louis, MO), mouse monoclonal anti-transforming growth factor-β1 (TGF-β1) antibody (sc-130348; Santa Cruz Biotechnology, Santa Cruz, CA), mouse monoclonal anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody (G8795; Sigma-Aldrich), rabbit monoclonal anti- phosphorylated Smad2 (p-Smad2) antibody (#3108; Cell Signaling Technology, Danvers, MA), mouse monoclonal anti-Smad2 antibody (#3103; Cell Signaling Technology), rabbit polyclonal anti-collagen type I (Col-I) antibody (ab6308; Abcam), rabbit polyclonal anti-collagen type III (Col-III) antibody (ab7778; Abcam), rabbit polyclonal anti-CD3 antibody (IR503; Dako, Santa Clara, CA), rabbit polyclonal anti-CD68 antibody (ab125212; Abcam), and rabbit monoclonal anti CD163 antibody (ab182422; Abcam).

**Other Materials**

Rat and human IFN-γ were obtained from PEPROTECH (Rocky Hill, NJ). A PGE2 high sensitivity ELISA kit was purchased from Enzo Life Science (ADI-930-001; Villeurbanne, France). Dulbecco’s modified Eagle’s medium (DMEM) was obtained from Sigma-Aldrich.

**Cell Culture**

Rat MSCs (rMSCs) were isolated from bone marrow of the SD rat femur and tibia. rMSCs were cultured in DMEM containing 10% fetal bovine serum (FBS; Sigma-Aldrich) for the primary culture. MSCs were passaged four times before used for administration or in vitro experiments. These cells were confirmed as MSCs by promoting their differentiation into osteocytes and adipocytes with specific differentiation media [29]. Furthermore, we confirmed that standard MSC surface markers CD44 and CD90 were positive in these cells by flow cytometry. Human bone marrow MSCs (hMSCs) and human THP-1 monocytes were purchased from Riken BRC (Ibaraki, Japan). HK-2 cells, a human proximal tubular cell line, were obtained from the American Type Culture Collection (Manassas, VA). These cells were cultured as described previously [28].
Cell Preparation for *in vivo* Experiments

rMSCs (3 × 10^5 cells/100-mm dish) were seeded and cultured in DMEM supplemented with 10% FBS. At 80% confluence, the medium was replaced by fresh medium with or without 200 ng/ml IFN-γ, and the cells were cultured for 24 hours. The cells were resuspended in PBS and subjected to *in vivo* analyses as IFN-γ-treated rMSCs (IFN-γ rMSCs) or untreated rMSCs (control rMSCs).

Preparation of Conditioned Medium (CM)

After hMSCs or rMSCs were grown to 80% confluence in DMEM supplemented with 10% FBS, the medium was replaced by fresh medium with or without 200 ng/ml IFN-γ. Twenty-four hours later, the medium was replaced by DMEM supplemented with 0.1% FBS, which was collected after 24 or 48 hours.

Cell Treatment with TGF-β1

After incubation in DMEM supplemented with 0.1% FBS, CM from control hMSCs, or CM from hMSCs treated with IFN-γ for 24 hours, human HK-2 cells were treated with 10 ng/ml recombinant human TGF-β1 (R&D Systems, Minneapolis, MN). Thirty minutes or 24 hours later, the cells were collected and subjected to analysis of TGF-β1-induced fibrotic changes.

Polarization of M2 Macrophages

To induce differentiation of THP-1 monocytes into M1 macrophages, THP-1 cells were stimulated by 160 nM phorbol 12-myristate 13-acetate (Sigma-Aldrich) for 48 hours. The medium was replaced by DMEM supplemented with 0.1% FBS, control hMSC-CM, or IFN-γ hMSC-CM. After 48 hours, the cells were collected and subjected to western blot analysis of CD163 and CD68.

Transfection with Prostaglandin E Synthase (PTGES) siRNA

rMSCs and hMSCs were transfected with 20 nM siRNA against PTGES (s133104 and s18305; Applied Biosystems, Waltham, MA) or negative control siRNA (4390843; Applied Biosystems) using Lipofectamine 2000 Transfection Reagent (Thermo Fisher Scientific). Cells were cultured in DMEM supplemented with 10% FBS for 5 days and then subjected to *in vitro* and *in vivo* analyses.

Preparation of an IRI Model and MSC Administration

A rat IRI model, an acute kidney injury (AKI) model, was used to analyze the progression from AKI to CKD. Rats were anesthetized by intraperitoneal injection of three types of mixed anesthetic agents (butorphanol, medetomidine, and midazolam). The left renal artery was clamped to induce ischemia. Sixty minutes later, the clamp was opened and reperfusion of blood was confirmed. After confirmation of reperfusion, PBS (vehicle), control MSCs, or IFN-γ rMSCs (5 × 10^5 cells/rat) were injected into the abdominal aorta. After 7 or 21 days, the rats were sacrificed and their kidneys were collected to evaluate inflammation and chronic fibrosis.

Preparation of a UUO Model and MSC Administration

A UUO model, which is an experimental renal fibrosis model, was prepared to investigate the anti-fibrotic effect of MSCs. Rats were anesthetized by the same procedure described for the IRI model. The left ureter was exposed after an abdominal midline incision and ligated to induce UUO. At 4 days after the UUO operation, PBS, control rMSCs, or IFN-γ rMSCs (2.5 × 10^6 cells/rat) were injected into the tail vein. After 7 days, the rats were sacrificed and examined for renal fibrosis.

Western Blotting

Sample preparation and western blotting were performed as described previously [28]. The protein bands were quantified using ImageJ software (version 1.47v; National Institutes of Health) and normalized to GAPDH levels.

Immunohistochemical Analysis
Left kidneys of IRI and UUO rats were fixed in 10% formaldehyde for 18 hours. Fixed samples were embedded in paraffin and cut into 4 µm-thick sections. Immunohistochemical staining of kidneys was performed for light microscopic observation. Five fields (×100) of the renal cortex were selected randomly. CD3-, CD68-, and CD163-positive cells and areas positive for α-SMA, Col-I, and Col-III were assessed using ImageJ software.

**Enzyme-linked Immunosorbent Assay (ELISA)**

To evaluate the amount of PGE2 in CM, the ELISA was performed according to the manufacturer’s instructions. PGE2 concentrations were normalized to the total protein content of MSCs.

**Quantitative Real-time Reverse Transcription-PCR**

RNA extraction and quantitative reverse transcription-PCR were performed as described previously [30]. mRNA levels were normalized to the level of 18 s rRNA. Primers and TaqMan probes (TaqMan Gene Expression Assay) were obtained from Applied Biosystems (Foster City, CA). The probe set ID for rat PTGES is Rn00572047_m1 and for human PTGES is Hs00610420_m1.

**Statistical Analysis**

All results are expressed as the mean ± standard deviation (SD). Statistical analysis for multiple comparisons was performed using one-way ANOVA followed by Bonferroni’s post-hoc test. The Student’s t-test was performed to compare the difference between two groups. p < 0.05 was defined as statistically significant.

**Results**

**Expression of HMGB1, IL-18, and IFN-γ in the kidney after the IRI procedure**

HMGB1 and IL-18, which are known as DAMPs, are released from damaged tissues. Released IL-18, which is also induced by HMGB1, contributes to secretion of IFN-γ [9, 17]. To confirm expression of HMGB1, IL-18, and IFN-γ induced by IRI, rats were sacrificed to evaluate their expression in the kidney at 1 day (Post IRI Day 1) and 7 days (Post IRI Day 7) after the IRI procedure. As shown in a previous study [31], the protein level of HMGB1 was increased by the IRI procedure (Fig. 1a). Immunostaining revealed that IL-18 and IFN-γ-positive areas were increased strongly in the kidney at 1 day after IRI. However, their increase was attenuated at 7 days after IRI (Fig. 1b, 1c).

MSCs are activated by released IFN-γ and exert immunosuppressive effects [20-22]. Therefore, administration of MSCs cultured in IFN-γ-containing medium may have beneficial effects on preventing the progression of renal fibrosis.

**IFN-γ enhances the ability of MSCs to attenuate fibrosis induced by IRI**

MSCs have been reported to suppress fibrosis by inhibiting inflammatory cell infiltration [28, 29]. In addition, the anti-inflammatory effects of MSCs can be enhanced by IFN-γ [20]. To evaluate anti-fibrotic effects of MSCs, we injected PBS, IFN-γ rMSCs or control rMSCs into the abdominal aorta of rats after ischemic reperfusion. Twenty-one days later, the rats were sacrificed, and injured kidneys were collected to evaluate the degree of fibrosis by western blotting.

The protein levels of α-SMA and TGF-β1, markers for drivers of fibrosis, were increased in the kidney of PBS-injected rats and their levels were suppressed by injection of control rMSCs (Fig. 2a). Furthermore, injection of IFN-γ rMSCs decreased IRI-induced fibrotic changes more significantly than that of control rMSCs (Fig. 2a). Immunostaining of α-SMA, Col-I, and Col-III (extracellular matrix proteins) was also performed to assess renal fibrosis. α-SMA, Col-I, and Col-III-positive areas were increased in the PBS group. Similar to the results from western blotting, administration of IFN-γ rMSCs reduced α-SMA, Col-I, and Col-III-positive areas more strongly compared with that of control rMSCs (Fig. 2b, 2c). These results suggest that IFN-γ-preconditioned rMSCs have a strong anti-fibrotic effect.
IFN-γ enhances the ability of MSCs to suppress inflammation induced by IRI

As shown above, IFN-γ rMSCs strongly suppressed renal fibrosis in IRI rats. We next examined the anti-inflammatory effects of IFN-γ rMSCs in the acute phase of renal injury in IRI rats. rMSCs with or without IFN-γ treatment were injected into rats after IRI induction, and 7 days later, the rats were sacrificed to investigate infiltration of inflammation cells into the kidney.

Immunostaining showed that infiltration of CD3 (T cell marker)- and CD68 (macrophage marker)-positive cells was markedly increased in the PBS group (Fig. 3a, 3b). Injection of control rMSCs suppressed the infiltration of these cells, and the suppression was more significant in the IFN-γ rMSCs group (Fig. 3a, 3b). However, the infiltration of CD163 (immunosuppressive macrophage marker)-positive cells was increased by injection of control rMSCs, and injection of IFN-γ rMSCs resulted in a more significant increase in CD163-positive cells (Fig. 3a, 3b), indicating that IFN-γ-preconditioned rMSCs have a stronger anti-inflammatory effect.

Administration of IFN-γ-preconditioned MSCs strongly attenuates UUO-induced fibrosis

A UUO model was used to confirm the anti-fibrotic effect of IFN-γ rMSCs. Four days after UUO, rats were injected with PBS, control rMSCs, or IFN-γ rMSCs through the tail vein. Seven days after injection, the rats were sacrificed and evaluated for renal fibrosis.

Western blotting showed that expression of α-SMA was induced by UUO in the PBS group. The protein levels of α-SMA were suppressed by injection of control rMSCs, and the suppression of α-SMA levels by IFN-γ rMSCs was more significant than that by control rMSCs (Fig. 4a). Immunostaining also revealed increases in α-SMA, Col-I, and Col-III-positive areas in the PBS group. These fibrotic changes were suppressed by injection of control rMSCs, and stronger suppressive effects on fibrosis were observed in rats injected with IFN-γ rMSCs compared with control rMSCs (Fig. 4b, 4c).

Conditioned medium from IFN-γ-preconditioned MSCs strongly inhibits TGF-β1/Smad signaling in a paracrine fashion

The TGF-β1/Smad signaling pathway is known to induce renal fibrosis. To investigate whether MSCs treated with IFN-γ strongly inhibit TGF-β1/Smad signaling in a paracrine fashion, we used CM from hMSCs treated with IFN-γ (IFN-γ hMSCs) or untreated hMSCs (control hMSCs).

The protein levels of p-Smad2 and α-SMA in HK-2 cells were increased by TGF-β1 stimulation, and the increased levels were reduced by incubation in CM from control hMSCs (Fig. 5a, 5b). CM from IFN-γ hMSCs showed stronger suppressive effects than that from control hMSCs (Fig. 5a, 5b). These findings suggest that IFN-γ-preconditioned hMSCs strongly inhibit the TGF-β1/Smad signaling pathway.

IFN-γ enhances secretion of PGE2 from MSCs

Anti-inflammatory and anti-fibrotic activities of MSCs treated with IFN-γ are regulated in a paracrine manner. It has been reported that secretion of PGE2 from MSCs exerts anti-inflammatory effects [23–25]. Thus, the amount of PGE2 contained in CM from IFN-γ hMSCs and control hMSCs was measured by an ELISA. The amount of PGE2 was significantly elevated in CM from control hMSCs. Furthermore, the levels of secreted PGE2 were more markedly increased in CM from IFN-γ hMSCs (Fig. 5c).

IFN-γ-preconditioned MSCs promote a change in the phenotype of macrophages from M1 to M2

PGE2 has been reported to promote polarization of M2 macrophages (immunosuppressive macrophages) and exert anti-inflammatory effects [26, 27]. The phenotypic change of macrophages from M1 (proinflammatory macrophages) to M2 is considered as one of the reasons for the anti-inflammatory effects of MSCs. We investigated whether MSCs treated with IFN-γ affect the phenotypic change of macrophages using monocytic THP-1 cells. THP-1 cells were stimulated with phorbol 12-myristate 13-acetate to induce differentiation into macrophages. Then, the medium was replaced with 0.1% PBS-containing medium or CM from either control hMSCs or IFN-γ hMSCs. Forty-eight hours after medium replacement, the cells were collected and expression of CD163 and CD68 was evaluated. Although there was no significant difference in the protein levels of CD68,
those of CD163 were upregulated by CM from control hMSCs (Fig. 5d). Furthermore, CM from IFN-γ hMSCs resulted in stronger induction of CD163 compared with that from hMSCs, indicating increased infiltration of CD163-positive immunosuppressive macrophages.

**Knockdown of PTGES weakens the ability of IFN-γ-preconditioned MSCs to change the phenotype of macrophages to immunosuppressive M2**

We hypothesized that the potent anti-fibrotic and anti-inflammatory effects of IFN-γ MSCs were due to increased secretion of PGE2. First, we investigated whether PTGES siRNA affected the anti-fibrotic ability of IFN-γ hMSCs using HK2 cells and CM. hMSCs were transfected with PTGES siRNA or negative control siRNA (NC siRNA) for 12 hours. After transfection, hMSCs were stimulated by IFN-γ for 24 hours. IFN-γ hMSCs transfected with PTGES siRNA showed significant decreases in PTGES mRNA (Additional file 1a). Although the protein levels of α-SMA in HK-2 cells were decreased by incubation in CM from IFN-γ hMSCs transfected with NC siRNA, there was no significant difference between NC siRNA and PTGES siRNA groups (Additional file 1b). Next, to identify the effects of PTGES siRNA on the phenotypic change of macrophages, THP-1 monocytes were stimulated with PMA. After 48 hours, the medium was replaced with 0.1% FBS-containing medium or CM from IFN-γ hMSCs transfected with NC siRNA or PTGES siRNA. After the medium replacement, the cells were collected to evaluate expression of CD163 and CD68. The protein levels of CD163 were increased by CM from IFN-γ hMSCs transfected with PTGES siRNA (Fig. 6a). However, the upregulation of CD163 was suppressed by CM from IFN-γ hMSCs transfected with PTGES siRNA.

**Knockdown of PTGES weakens the anti-fibrotic effect of IFN-γ-preconditioned MSCs in IRI models**

IFN-γ-precondition enhanced the expression of PTGES mRNA in rMSCs (Additional file 2a) and IFN-γ rMSCs transfected with PTGES siRNA showed significant decreases in PTGES mRNA and secreted PGE2 (Additional file 2b and Fig. 7a). PTGES siRNA-transfected IFN-γ rMSCs (PTGES siRNA IFN-γ rMSCs) and NC siRNA-transfected IFN-γ rMSCs (NC siRNA IFN-γ rMSCs) were administered to IRI rats to examine whether PTGES siRNA affects the anti-fibrotic effect of IFN-γ rMSCs. After preparation of IRI rats, either type of rMSCs were injected into the abdominal aorta, and 21 days later, rats were sacrificed to evaluate fibrosis. Western blotting revealed that the protein levels of α-SMA and TGF-β1 were decreased by NC siRNA IFN-γ rMSCs. However, these decreases were weakened by PTGES siRNA IFN-γ rMSCs (Fig. 7b, 7c). Similarly, immunostaining showed strong suppression of α-SMA and Col-III-positive areas by NC siRNA IFN-γ rMSCs. These anti-fibrotic effects were attenuated by PTGES siRNA IFN-γ rMSCs (Fig. 7d, 7e). These results support the hypothesis that the potent renal anti-fibrotic effect of IFN-γ MSCs depends on increased secretion of PGE2.

**Discussion**

Here, we provide the first evidence that administration of MSCs treated with IFN-γ strongly ameliorates renal fibrosis and inflammation in rat IRI and UUO models compared with that of untreated MSCs. Furthermore, CM from MSCs stimulated by IFN-γ inhibits TGF-β/Smad signaling *in vitro*. IFN-γ stimulation promotes the secretion of PGE2 from MSCs, and increased PGE2 induces polarization of immunosuppressive CD163-positive macrophages. Knockdown of PTGES attenuates the anti-fibrotic effect of IFN-γ-treated MSCs in IRI rats. These findings suggest that MSCs treated with IFN-γ have a great potential to suppress renal fibrosis.

DAMPs, such as HMGB1 and IL-18, are involved in the induction and repression of inflammation [7]. HMGB1 released from damaged tissues cooperates with cytokines, such as those secreted from macrophages, to induce inflammation [32–34]. HMGB1 is also involved in inducing IL-18 production [9]. Induced IL-18 promotes secretion of IFN-γ from natural killer cells [19]. When MSCs cultured under normal conditions are administered to renal injured rats, MSCs can be activated by IFN-γ secreted from natural killer cells in injured tissues and suppress renal inflammation [19]. These processes may require several days, leading to a delay of the onset of MSCs immunosuppressive effects. Because anti-inflammation and anti-fibrotic effects of MSCs treated with IFN-γ were enhanced in advance, their strong therapeutic effects appear to be exerted immediately after administration.

Several studies have reported that IFN-γ enhances secretion of PGE2, the major metabolite of arachidonic acid
PGE2 promotes polarization of immunosuppressive M2 macrophages through induction of the cyclic adenosine monophosphate pathway, resulting in a strong anti-inflammatory effect [26]. In this study, MSCs treated with IFN-γ produced increased amounts of PGE2, leading to more pronounced polarization of M2 macrophages. These results are consistent with a previous in vitro study on mouse MSCs [20]. Therefore, we speculated that PGE2 might contribute to the immunosuppressive action of MSCs in vivo. In fact, we found that knockdown of PTGES weakened the anti-fibrotic effect of MSCs treated with IFN-γ in IRI rats. Thus, the upregulation of PGE2 in MSCs plays an important role in anti-inflammation and anti-fibrotic effects of MSCs treated with IFN-γ.

The TGF-β/Smad signaling pathway is considered as one of the processes that cause renal fibrosis. TGF-β is a soluble factor that binds to a cell surface receptor, and phosphorylates and activates Smad2. Phosphorylated Smad2 induces expression of the αSMA gene and promotes fibrosis [36, 37]. The damaged tissues produce TGF-β that induces renal fibrosis via the TGF-β/Smad signaling pathway. Whereas, TGF-β exerts anti-inflammatory effects, and TGF-β blockade may lead to autoimmune disease [38, 39]. Thus, inhibition of the TGF-β/Smad signaling pathway, but not TGF-β itself, may be a key mechanism by which MSCs treated with IFN-γ suppress renal fibrosis. Therefore, in this study, we investigated whether CM from IFN-γ-preconditioned MSCs strongly inhibits the induction of phosphorylated Smad2 and α-SMA by TGF-β. Western blotting showed that CM from IFN-γ-preconditioned MSCs significantly decreased TGF-β-induced fibrotic changes compared with that from untreated MSCs. These results suggest that IFN-γ-preconditioned MSCs exert strong anti-fibrotic effects through direct inhibition of the TGF-β/Smad signaling pathway.

Conclusions

We show that renal fibrosis and inflammation are strongly attenuated by injection of IFN-γ-treated MSCs in IRI and UUO rats. The anti-inflammation and anti-fibrotic effects of MSCs treated with IFN-γ are due to direct inhibition of TGF-β/Smad signaling and enhancement of PGE2 secretion, which polarization of immunosuppressive M2 macrophages. As a result, administration of MSCs treated with in IFN-γ may provide a promising therapeutic approach to prevent the progression of renal fibrosis.

Abbreviations

α-SMA: α-smooth muscle actin; AKI: acute kidney injury; CKD: chronic kidney disease; Col-I: collagen type I; Col-III: collagen type III; CM: conditioned medium; DMEM: Dulbecco’s modified Eagle’s medium; DAMPs: Damage-associated molecular patterns; ELISA: enzyme-linked immunosorbent assay; FBS: fetal bovine serum; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; HMGB1: high mobility group box-1 protein; IL-18: interleukin-18; IFN-γ: interferon-γ; IRI: ischemia-reperfusion injury; MSCs: Mesenchymal stem cells; rMSCs: rat MSCs; IFN-γ rMSCs: rMSCs with IFN-γ treatment; control rMSCs: rMSCs without IFN-γ treatment; hMSCs: human bone marrow MSCs; IFN-γ hMSCs: hMSCs with IFN-γ treatment; control hMSCs: hMSCs without IFN-γ treatment; PTGES: prostaglandin E Synthase; NC: negative control; PTGES siRNA IFN-γ rMSCs: PTGES siRNA-transfected IFN-γ rMSCs; NC siRNA IFN-γ rMSCs: NC siRNA-transfected IFN-γ rMSCs; PGE2: prostaglandin E2; p-Smad2: phosphorylated Smad2; TGF-β1: transforming growth factor-β1; UUO: unilateral ureter obstruction

Declarations

Availability of data and materials

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Ethics approval and consent to participate
All experimental procedures were approved by the Institutional Animal Care and Use Committee of Hiroshima University (Permit number: A15-66 and A17-75).

**Consent for publication**

Not applicable.

**Competing interests**

The Department of Stem Cell Biology and Medicine, Graduate School of Biomedical & Health Sciences, Hiroshima University is a collaborative research laboratory funded by TWOCELLS Company, Limited. Dr. Maeda is the Deputy Division Manager of R&D Division II, Head Office of Research and Development of TWOCELLS Company, Limited. Emeritus Prof. Kato is the Vice President of TWOCELLS Company, Limited. Except for the abovementioned disclosures, all authors have declared that no conflict of interest exists.

**Funding**

This study was supported in part by JSPS KAKENHI Grant Number JP17K09699. A part of this work was carried out at the Analysis Center of Life Science, Natural Science Center for Basic Research and Development, Hiroshima University.

**Author contributions**

A.N. and T.M. designed the study; R.K., A.N., T.K., K.Y., S.M., N.I, Y.Y., T.I., and T.D. carried out experiments; R.K., S.D., N.I. and Y.K. analyzed the data; R.K. and A.N. drafted and revised the paper. All authors read and approved the final manuscript.

**Acknowledgments**

We would like to express our gratitude to Dr. Mikihito Kajiya of the Department of Periodontal Medicine, Graduate School of Biomedical & Health Sciences, Hiroshima University for his insightful advice on the experimental design. We would like to thank Prof. Takeshi Kawamoto of the Writing Center, Hiroshima University and Mitchell Arico from Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript. We also thank Ms. Miki Kagiya for technical assistance.

**References**

1. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382:260–72.
2. Xie Y, Bowe B, Mokdad AH, Xian H, Yan Y, Li T, et al. Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney Int. 2018;94:567–81.
3. Lee SB, Kalluri R. Mechanistic connection between inflammation and fibrosis. Kidney Int. 2010;78:22–6.
4. Meng XM, Nikolic-Paterson DJ, Lan HY. Inflammatory processes in renal fibrosis. Nat Rev Nephrol. 2014;10:493–503.
5. Eirin A, Lerman LO. Mesenchymal stem cell treatment for chronic renal failure. Stem Cell Res Ther. 2014;5:83.
6. Zeisberg M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol. 2010;21:1819–34.
7. Rosin DL, Okusa MD. Dangers within: DAMP responses to damage and cell death in kidney disease. J Am Soc Nephrol. 2011;22:416–25.
8. Anders HJ, Schaefer L. Beyond tissue injury-damage-associated molecular patterns, toll-like receptors, and inflammasomes also drive regeneration and fibrosis. J Am Soc Nephrol. 2014;25:1387–400.
9. He Q, You H, Li XM, Liu TH, Wang P, Wang BE. HMGB1 promotes the synthesis of pro-IL-1β and pro-IL-18 by activation of p38 MAPK and NF-kB through receptors for advanced glycation end-products in macrophages. Asian Pac J Cancer Prev. 2012;13:1365–70.
10. Zewinger S, Schumann T, Fliser D, Speer T. Innate immunity in CKD-associated vascular diseases. Nephrol Dial Transplant. 2016;31:1813–21.

11. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143–7.

12. Weissman IL. Stem cells: units of development, units of regeneration, and units in evolution. Cell. 2000;100:157–68.

13. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem. 2006;98:1076–84.

14. Chen Y, Shao JZ, Xiang LX, Dong XJ, Zhang GR. Mesenchymal stem cells: a promising candidate in regenerative medicine. Int J Biochem Cell Biol. 2008;40:815–20.

15. Meirelles Lda S, Fontes AM, Covas DT, Caplan AI. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev. 2009;20:419–27.

16. Hocking AM, Gibran NS. Mesenchymal stem cells: paracrine signaling and differentiation during cutaneous wound repair. Exp Cell Res. 2011;316:2213–9.

17. Meng E, Guo Z, Wang H, Jin J, Wang J, Wang H, et al. High mobility group box 1 protein inhibits the proliferation of human mesenchymal stem cells and promotes their migration and differentiation along osteoblastic pathway. Stem Cell Dev. 2008;17:805–13.

18. Lin F, Zhang W, Xue D, Zhu T, Li J, Chen E, et al. Signaling pathways involved in the effects of HMGB1 on mesenchymal stem cell migration and osteoblastic differentiation. Int J Mol Med. 2016;37:789–97.

19. Thomas H, Jäger M, Mauel K, Brandau S, Lask S, Flohé SB. Interaction with mesenchymal stem cells provokes natural killer cells for enhanced IL-12/IL-18-induced interferon-gamma secretion. Mediators Inflamm. 2014;2014:143463.

20. Lin T, Pajarinen J, Nabeshima A, Lu L, Nathan K, Jämersen E, et al. Preconditioning of murine mesenchymal stem cells synergistically enhanced immunomodulation and osteogenesis. Stem Cell Res Ther. 2017;8:277.

21. English K. Mechanisms of mesenchymal stromal cell immunomodulation. Immunol Cell Biol. 2013;91:19–26.

22. English K, Barry FP, Field-Corbett CP, Mahon BP. IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol Lett. 2007;110:91–100.

23. Takayama K, García-Cardena G, Sukhova G, Comander J, Gimbrone MA Jr, Libby P. Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor. J Biol Chem. 2002;277:44147–54.

24. Ogawa M, Suzuki J, Kosuge H, Takayama K, Nagai R, Isobe M. The mechanism of anti-inflammatory effects of prostaglandin E2 receptor 4 activation in murine cardiac transplantation. Transplantation. 2009;87:1645–53.

25. Frolov A, Yang L, Dong H, Hammock BD, Crofford LJ. Anti-inflammatory properties of prostaglandin E2: deletion of microsomal prostaglandin E synthase-1 exacerbates non-immune inflammatory arthritis in mice. Prostaglandins Leukot Essent Fatty Acids. 2013;89:351–8.

26. Luan B, Yoon YS, Lay JL, Kaestner KH, Hedrick S, Montminy M. CREB pathway links PGE2 signaling with macrophage polarization. Proc Natl Acad Sci USA. 2015;112:15642–7.

27. Jin L, Deng Z, Zhang J, Yang C, Liu J, Han W, et al. Mesenchymal stem cells promote type 2 macrophage polarization to ameliorate the myocardial injury caused by diabetic cardiomyopathy. J Transl Med. 2019;17:251.

28. Yoshida K, Nakashima A, Doi S, Ueno T, Okubo T, Kawano KI, et al. Serum-Free Medium Enhances the Immunosuppressive and Antifibrotic Abilities of Mesenchymal Stem Cells Utilized in Experimental Renal Fibrosis. Stem Cells Transl Med. 2018;7:893–905.

29. Ueno T, Nakashima A, Doi S, Kawamoto T, Honda K, Yokoyama Y, et al. Mesenchymal stem cells ameliorate experimental peritoneal fibrosis by suppressing inflammation and inhibiting TGF-β1 signaling. Kidney Int. 2013;84:297–307.

30. Nakashima A, Kawamoto T, Honda K, Ueshima T, Noshiro M, Iwata T, et al. DEC1 modulates the circadian phase of clock gene expression. Mol Cell Biol. 2008;28:4080–92.

31. Huiling W, Jin M, Peng W, Corpuz TM, Panchapakesan U, Wyburn KR, et al. HMGB1 Contributes to Kidney Ischemia Reperfusion Injury. J Am Soc Nephrol. 2010;21:1878–90.

32. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002;418:191–5.
33. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005;5:331–42.
34. Lu B, Wang C, Wang M, Li W, Chen F, Tracey KJ, et al. Molecular mechanism and therapeutic modulation of high mobility group box 1 release and action: an updated review. Expert Rev Clin Immunol. 2014;10:713–27.
35. Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011;31:986–1000.
36. Li Y, Dai C, Wu C, Liu Y. PINCH-1 Promotes Tubular Epithelial-to-Mesenchymal Transition by Interacting with Integrin-Linked Kinase. J Am Soc Nephrol. 2007;18:2534–43.
37. Phanish MK, Wahab NA, Colville-Nash P, Hendry BM, Dockrell ME. The differential role of Smad2 and Smad3 in the regulation of pro-fibrotic TGFbeta1 responses in human proximal-tubule epithelial cells. Biochem J. 2006;393:601–7.
38. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, et al. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature. 1992;359:693–9.
39. Yoshimura A, Wakabayashi Y, Mori T. Cellular and molecular basis for the regulation of inflammation by TGF-β. J Biochem. 2010;147:781–92.
Expression of HMGB1, IL-18, and IFN-γ in the kidney after the IRI procedure. Rats were sacrificed at 1 day (Post IRI Day 1) and 7 days (Post IRI Day 7) after the IRI procedure and evaluated for expression of HMGB1, IL-18, and IFN-γ. aWestern blot analysis of HMGB1 in the rat kidney cortex. Protein levels were normalized to GAPDH levels (n = 5 in each group). bRepresentative immunohistochemical staining of IL-18 and IFN-γ in kidney sections (scale bar, 100 µm). cQuantification of IL-18 and IFN-γ-positive areas (n = 5 in each group). Data are presented as the mean ± SD. *p < 0.05, **p < 0.01. Sham, non-IRI procedure.
Figure 2
Anti-fibrotic effects of IFN-γ-treated MSCs in the kidney of IRI rats. IFN-γ-treated or untreated rat MSCs were injected immediately after IRI induction. Twenty-one days later, protein levels of fibrosis markers were evaluated by western blot and immunohistochemical analyses. a Western blot analysis of α-SMA and TGF-β1 in the rat kidney cortex. Protein levels were normalized to GAPDH levels (n = 5 in each group). b Representative immunohistochemical staining of α-SMA, Collagen type I (Col-I), and Collagen type III (Col-III) in kidney sections. (scale bar, 100 µm). c Quantification of α-SMA-, Col-I-, and Col-III-positive areas (n = 5 in each group). Data are presented as the mean ± SD. **p < 0.01. Sham, non-IRI procedure; PBS, PBS injection; control rMSCs, rat MSCs injection; IFN-γ rMSCs, injection of IFN-γ-treated rMSCs.
Figure 3

Anti-inflammatory effects of IFN-γ-treated MSCs in IRI rats. Infiltration of T cells and macrophages into injured kidney of MSC-injected IRI rats was assessed at 7 days after IRI by immunostaining. a Representative immunohistochemical staining of CD3, CD68, and CD163 in rat kidney sections (scale bar, 100 µm). b Quantification of CD3, CD68, and CD163-positive cells (n = 5 in each group). Data are presented as the mean ±
SD. **p < 0.01. Abbreviations are as in Figure 2.
Anti-fibrotic effects of IFN-γ-treated MSCs in UUO rats. Rat MSCs with or without IFN-γ treatment were injected at 4 days after the UUO procedure. After 11 days, protein levels of fibrosis markers were evaluated by western blot and immunohistochemical analyses. 
a Western blot analysis of α-SMA in the rat kidney cortex. Protein levels were normalized to GAPDH levels (n = 5 in each group). 
b Representative immunohistochemical staining of α-SMA, Col-I, and Col-III in rat kidney sections (scale bar, 100 µm). 
c Quantification of α-SMA-, Col-I-, and Col-III-positive areas (n = 5 in each group). Data are presented as the mean ± SD. **p< 0.01. Sham, non-UUO procedure; Other abbreviations are defined in the Figure 2 legend.
Paracrine effects of IFN-γ-treated hMSCs on the TGF-β/Smad signaling pathway and phenotypic changes of macrophages. a, b After HK-2 cells, a human proximal tubular cell line, were incubated with conditioned medium (CM) obtained from IFN-γ-treated or untreated hMSCs for 24 hours, the cells were treated with TGF-β1 for 30 min (a) or 24 hours (b). a Western blot analysis of phosphorylated Smad2 (p-Smad2) and Smad2 in HK-2 cells. p-Smad2 protein levels were normalized to Smad2 levels (n = 5 in each group). b Western blot analysis of α-SMA in HK-2 cells. α-SMA protein levels were normalized to GAPDH levels (n = 5 in each group). Control hMSCs, CM from hMSCs without IFN-γ treatment; IFN-γ hMSCs, CM from hMSCs treated with IFN-γ. c Concentration of PGE2 in CM from hMSCs was evaluated by an ELISA at 24 or 48 hours after IFN-γ stimulation. HK-2 cells were used as a negative control (n = 5 in each group). HK-2, CM from HK-2 cells. d Phenotypic changes of macrophages were evaluated by CD163 and CD68 protein levels. To induce differentiation of monocytic THP-1 cells into macrophages, the cells were treated with PMA for 48 hours. The induced THP-1 cells were incubated with CM from IFN-γ-treated or untreated hMSCs. After 48 hours, the cells were harvested and subjected to western blot analysis of CD163 and CD68. CD163 protein levels were normalized to the GAPDH and CD68 levels (n = 5 in each group). Data are presented as the mean ± SD. *p < 0.05, **p < 0.01.
Figure 6

Effects of PTGES siRNA in IFN-γ-treated hMSCs on the phenotypic change of macrophages. aTHP-1 monocytes were stimulated by PMA for 48 hours and then incubated with CM from IFN-γ-treated hMSCs transfected with negative control (NC) siRNA or prostaglandin E synthase (PTGES) siRNA. After 48 hours, the cells were collected and subjected to western blot analysis of CD163 and CD68. CD163 protein levels were normalized to GAPDH and CD68 levels (n = 5 in each group). Data are presented as the mean ± SD. *p < 0.05, **p < 0.01.
Figure 7

Inhibitory effects of PTGES siRNA on the anti-fibrotic effects of IFN-γ-treated rMSCs in IRI rats. After rMSCs transfected with NC siRNA or PTGES siRNA were treated with IFN-γ, the cells were injected into rats immediately after IRI induction. Twenty-one days later, protein levels of fibrosis markers in the kidney were evaluated by western blot and immunohistochemical analyses. a Secreted PGE2 levels in CM from IFN-γ-treated rMSCs transfected with NC siRNA or PTGES siRNA were evaluated by an ELISA (n = 5 in each group). b, c Western blot analysis of α-SMA and TGF-β1 in the rat kidney cortex of IRI rats. Protein levels were normalized to GAPDH levels (n = 4 in each group). Sham, non-IRI procedure; PBS, PBS injection; NC siRNA, injection of IFN-γ rMSCs transfected with NC siRNA; PTGES siRNA, injection of IFN-γ rMSCs transfected with PTGES siRNA. d Representative immunohistochemical staining of α-SMA and Col-III in kidney sections (scale bar, 100 µm). e Quantification of α-SMA- and Col-III-positive areas (n = 4 in each group). Data are presented as the mean ± SD. *p < 0.05, **p < 0.01.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- SupplementalFigureLegends.docx
- SupplementalMaterial.pdf